1. Ambrsio A. F., Soares-da-Silva P., Carvalho C. M., Carvalho A. P., Mechanisms of
Action of Carbamazepine and Its Derivatives, Oxcarbazepine, BIA 2-093, and BIA 2-024, Neurochemical Research, Vol. 27, Nos. 1/2, Feb. 2002, pp. 12130 2. Bllu D., Baconi D., Toxicologia substanelor medicamentoase de sintez, Ed. Tehnoplast, Bucureti, 2005; 29-30, 152-59. 3. Benjamin S. M. (Editor), Focus on Epilepsy Research, Nova Biomedical Books, New York, 2004; 202-10 4. Berg AT, Shinnar S. The risk of seizure recurrence following a first unprovoked seizure: a quantitative review. Neurology 1991; 41: 96572. 5. Brewerton T. D., Jackson C.W., "Prophylaxis of carbamazepine-induced hyponatremia by demeclocycline in 6 patients." J Clin Psychiatry 55 (1994): 249-51 6. Clark B.J., Frost T., Russel M. A. (editor), UV Spectroscopy Techniques, instrumentation, data handling, Chapman and Hall, 1993; 1-2 7. Cristea A. N.(sub redacia), Tratat de farmacologie, Editura Medical, Bucureti, 2005; 128-31 8. Delzompo M, Bocchetta A, Loviselli A, Martino E, Post RM, Ketter TA "Thyroid function during carbamazepine." Biol Psychiatry 36 (1994): 135-6 9. Engel J., Jr., A Proposed Diagnostic Scheme for People with Epileptic Seizures and with Epilepsy: Report of the ILAE Task Force on Classification and Terminology, Epilepsia, Vol. 42, 2001: 796-803 10. Fisher, R. S., Cross, J. H., French, J. A., Higurashi, N., Hirsch, E., Jansen, F. E., Lagae, L., Mosh, S. L., Peltola, J., Roulet Perez, E., Scheffer, I. E. and Zuberi, S. M. (2017), Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology. Epilepsia, Vol 58: 52230 11. Gidal B. E, Zupanc M. L., Potential pharmacokinetic interaction between felbamate and phenobarbital, Annals of Pharmacotherapy, Apr., 1994; 12. Hauser WA, Hesdorffer DC. Epilepsy: frequency, causes, and consequences. New York: Demos Publications; 1990. 13. Hesdorffer D. C., Berg A.T, Kanner A. M,, An Update on Antiepileptic Drugs and Suicide: Are There Definitive Answers Yet?, Epilepsy Currents, Nov, 2010; 137-45 14. Hussein A., Abdulgalil A., Omer F., Eltoum H., Hamad A., El-Adil O., Mubarak B., Malkaldar M., Idris I., Alwidaa Y., Mahmoud E., Correlation between Serum Level of Antiepileptic Drugs and their Side Effects, Oman Medical Journal, 2010, Jan; 25(1); 17- 21 15. ILAE, Proposal for Revised Clinical and Electroencephalographic Classification of Epileptic Seizures, Epilesia, Vol. 22, 1981: 489501. 16. Jallon P., Use of mefloquine in epileptic patients, Journal of Nerurology, Neurosurgery and Psychiatry, 1988; May; 51(5): 732 17. Jasper H.H., Noebels J. L., M. Avoli, M. A. Rogawski, R.W. Olsen, A. V. Delgado - Escueta Jaspers Basic Mechanisms of the Epilepsies, Fourth Edition, 2012; 4-5 18. Jerome Engel, Jr, ILAE Classification of epilepsy syndromes, Epilepsy Research, Elsevier, 70S, 2006; S5-S10. 19. Kalff R, Houtkooper MA, Meyer JW, et al "Carbamazepine and serum sodium levels." Epilepsia 24 (1984): 390-7 20. Kuz G.M, Manssourian A., "Carbamazepine-induced hyponatremia: assessment of risk factors." Ann Pharmacother 39 (2005): 1943-6 21. Lofgren E, Tapanainen JS, Koivunen R, Pakarinen A, Isojarvi JI "Effects of carbamazepine and oxcarbazepine on the reproductive endocrine function in women with epilepsy." Epilepsia 47 (2006): 1441-6 22. Macdonald R. L., Kelly K. M., Antiepileptic Drug Mechanisms of Action, Epilepsia, Vol. 34, Suppl. 5, 1993 23. Mori H, Takahashi K, Mizutani T, Interaction between valproic acid and carbapenem antibiotics, Drug Metabolite Reviews, 2007;39(4):647-57. 24. Nica S., erbnescu A., Davidescu I., Epilepsia Reflex, Revista Romn de Neurologie, Nr 1, 2006; 23-26 25. Noh Y, Kim DW, Chu K, Lee ST, Jung KH, Moon HJ, Lee SK, Topiramate increases the risk of valproic acid-induced encephalopathy, Epilepsia, 2013, Jan; 54 (1) 26. Panayiotopoulos C.P., A Clinical Guide to Epileptic Syndromes and their Treatment, Second edition, 2010; 27. Panea C., Bjenaru O., erbnescu A., Epilepsia Adultului Ghid de diagnostic i tratament, 27-31, 8-9, 39-52, Anexa 11 28. Parke-Davis, Division of Pfizer Inc. Phenytoin sodium capsules, extended release prescribing information. New York, NY; 2011 Aug. 29. Perkampus H.H., UV-VIS Spectroscopy and its Applications, Springer-Verlag Berlin Heidelberg, 1992; 2-10 30. Popescu F. D., Udritoiu I., Popescu F., Vieru M., Sindromul de hipersensibilitate la anticonvulsivante, Jurnalul Naional de Psihofarmacologie, Vol. 5, Nr 1,2, 2005; 31. Popescu V., Etiologia Convulsiilor Neonatale, Practica Medical, Vol.1, Nr. 3-4, 2006; 104-9 32. Rudolf G., Valenti M.P., Hirsch E. Genetic reflex epilepsies. Orphanet Encyclopedia, 2004 33. Serma J., Fried B.(editor), Handbook of Thin Layer Cromatography, Third Edition, Revised and Expanded, Marel Dekker, Inc. 2003; 1-29 34. Simon Shorvon, Epilepsy, Oxford Universily Press, 2009; 1 35. Verrotti A, Basciani F, Morresi S, Morgese G, Chiarelli F "Thyroid hormones in epileptic children receiving carbamazepine and valproic acid." Pediatr Neurol 25 (2001): 43-6 36. Wu J.B., Valproic acid induces monoamine oxidase A via Akt/forkhead box O1 activation, Molecular Pharmacology, Oct., 2011; 37. ***Diaconu G., Convlusiile i epilepsiile, http://www.umfiasi.ro/Rezidenti/suporturidecurs/Facultatea%20de%20Medicina/Conf.dr. Diaconu%20Georgeta%20curs%20rezidenti/curs%20rezidenti%20- %20CONVULSIILE%20si%20EPILEPSIILE.doc 38. ***Novartis Pharmaceuticals Corporation. Tegretol (carbamazepine) chewable tablets, tablets, and suspension and Tegretol-XR (carbamazepine) extended-release tablets prescribing information. East Hanover, NJ; 2009 https://www.drugs.com/sfx/tegretol-side- effects.html 39. ***Sanofi-Aventis, Depakine Chrono, 500 mg, AUTORIZAIE DE PUNERE PE PIA NR. 1671/2009/01, Anexa 2 http://www.anm.ro/_/_RCP/rcp_1671_25.05.09.pdf